Published in Int J Biol Markers on December 01, 1992
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst (2001) 2.57
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med (2000) 1.93
Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol (1987) 1.57
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer (1999) 1.54
Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose. Eur J Nucl Med (1997) 1.42
[The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors]. Radiol Med (1997) 1.39
How alternative are immunoassay systems employing non-radioisotopic labels? A comparative appraisal of their main analytical characteristics. Q J Nucl Med (1995) 1.39
Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol (2000) 1.35
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol (2008) 1.31
Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol (2009) 1.30
Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med (1997) 1.18
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol (2001) 1.17
Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol (2013) 1.16
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med (1998) 1.11
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging (2011) 1.10
The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun (2004) 1.09
A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer (1998) 1.08
Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res (1986) 1.08
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem (1999) 1.07
A novel mutation in the ATP1A2 gene causes alternating hemiplegia of childhood. J Med Genet (2004) 1.07
Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments. Cancer Res (1985) 1.06
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res (2000) 1.04
Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia (2007) 1.04
Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep (1986) 1.04
Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med (2001) 1.03
A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging (2012) 1.01
Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med (1998) 0.99
Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging (2004) 0.98
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol (2002) 0.97
PET imaging in breast cancer. Q J Nucl Med (2001) 0.96
Point mutations and a large intragenic deletion in SPG11 in complicated spastic paraplegia without thin corpus callosum. J Med Genet (2009) 0.96
Sentinel lymph node mapping and biopsy for breast cancer: a review of the literature relative to 4791 procedures. Tumori (2000) 0.94
Structure, function and gene expression of epithelial mucins. Tumori (1997) 0.93
Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med (1998) 0.93
MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging (2008) 0.93
A simple loop method for the automated preparation of (11C)raclopride from (11C)methyl triflate. Appl Radiat Isot (2001) 0.91
Serum and cerebrospinal fluid human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) in intracranial germ cell tumors. Int J Biol Markers (2002) 0.89
The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res (2000) 0.88
The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas. Tumori (1997) 0.88
(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging (2010) 0.88
The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer (1999) 0.88
Pattern of mucin gene expression in normal and neoplastic lung tissues. Anticancer Res (1996) 0.87
Evaluation of the suitability of a monoclonal antibody raised against human ovarian carcinoma for therapeutic approaches. Int J Rad Appl Instrum B (1989) 0.87
Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. Int J Biol Markers (2005) 0.87
Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Eur J Cancer (1991) 0.87
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer (2004) 0.86
Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem (1994) 0.86
Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging (2015) 0.85
Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer (1995) 0.85
Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. Int J Biol Markers (1995) 0.85
Circulating tumor markers in breast cancer (review). Anticancer Res (1990) 0.85
The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res (2000) 0.85
Nuclear medicine advances in breast cancer imaging. Tumori (2001) 0.85
Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int J Biol Markers (1999) 0.84
Immunosuppressive factors: role in cancer development and progression. Int J Biol Markers (1999) 0.84
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol (2002) 0.83
A new, convenient method for the preparation of 4-[18F]fluorobenzyl halides. Appl Radiat Isot (2000) 0.83
Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med (2000) 0.82
Bone scintigraphy in breast cancer: a ten-year follow-up study. J Nucl Biol Med (1993) 0.82
Radioimmunodetection of melanoma: preliminary results of a prospective study. Int J Biol Markers (1988) 0.82
Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med (2000) 0.82
Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia. Clin Pharmacol Ther (2008) 0.82
European multicentre study on melanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. The European Multicentre Study Group. Eur J Nucl Med (1990) 0.81
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Invest New Drugs (2014) 0.81
Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer. Int J Oncol (1996) 0.81
p53 evaluation in gastric mucosa of patients with chronic Helicobacter pylori infection. Anticancer Res (2001) 0.81
Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging (2010) 0.81
A practical dead time correction method in planar activity quantification for dosimetry during radionuclide therapy. Q J Nucl Med Mol Imaging (2009) 0.81
Immunoscintigraphy of colorectal carcinoma with F (ab')2 fragments of anti-CEA monoclonal antibody. Cancer Detect Prev (1987) 0.81
Chromogranin A measurement in neuroendocrine tumors. Int J Biol Markers (1998) 0.81
Tumor radioimmunolocalization in a murine system using monoclonal antibodies. Tumori (1983) 0.81
Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM). J Nucl Med (1994) 0.81
Assessment of mediastinal involvement in lung cancer with technetium-99m-sestamibi SPECT. J Nucl Med (1996) 0.81
Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Surg Oncol (1996) 0.81
Diagnostic and prognostic tumor markers in the gastrointestinal tract. Semin Surg Oncol (2001) 0.81
Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res (1999) 0.81
Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res (1989) 0.81
False-negative sentinel node in patients with vulvar cancer: a case study. Int J Gynecol Cancer (2003) 0.81
A simple and semi-automated system for increasing the recovery of aqueous [18F] fluoride from target. Anticancer Res (1998) 0.81
Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med (1998) 0.80
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging (2009) 0.80
Artificial nutrition in cancer patients: which route, what composition? World J Surg (1999) 0.80